TARGET OA PAIN* THE WAY NOTHING ELSE DOES, AND KEEP DOGS AT THEIR OWNERS’ SIDES WITH GALLIPRANT™

A first-in-class piprant which works differently from COX-inhibiting NSAIDs¹
Specifically targets the EP4 receptor — the key mediator of OA pain¹
Does not interfere with homeostatic mechanisms mediated through other prostanoid receptors²
Treatment effect comparable to traditional NSAIDs^2,3

This means all dogs, young to old, can be treated early and for as long as needed.^†

REAL-LIFE SUCCESS STORIES

Galliprant has been in use for over 2 years in the UK and Ireland, helping dogs enjoy more special moments with their owners. As part of the Galliprant In Practice Case Series, Dr Ciaran Jones shares the story of Marble – a seven-year-old Labrador with elbow OA. Watch the one-minute clip below to see how Galliprant got Marble back in action so she could continue enjoying life with her active family.

Treatment for real life

Well tolerated over 9 months in a target animal safety study at doses equivalent to 15x the target dose⁴
No treatment was stopped or dogs removed from the study due to adverse events⁴
A simple, once-daily, chewable tablet that fits into daily routine
Most dogs can be dosed once a day with a whole or half tablet
No fixed monitoring schedule required on label, so any monitoring can be fitted around the owner and pet’s needs

This means Galliprant fits into everyday life, offering a reassuring long-term option for dogs diagnosed with OA in the prime of the lives.

HELP PET OWNERS SPOT THE SIGNS OF OA AND PROTECT THE MOMENTS THAT MATTER.

From disease education materials to professional training for vets, My OA Hero is designed to equip you with everything you need to educate pet owners about OA and initiate treatment for suitable cases.

DISCOVER MORE

Get the full details, videos and resources by logging into MyElanco.

Not registered yet? Don't miss out, see the benefits of MyElanco.

Galliprant Practice Brief (pdf)

A guide to the Galliprant materials available to your practice and how to access them.

Walking with Arthritis: Insights from Owners/Experts - Galliprant 1 hour CPD

Drs Zoe Belshaw and John Innes discuss the impact of canine arthritis on pets and their owners, including how to get the best possible outcomes - virtual setting or not.

Galliprant Brochure (pdf)

An easy-to-use vet brochure for Galliprant: the first-in-class piprant for dogs with osteoarthritis

‘101 Galliprant Dogs’ Infographic (pdf)

Presenting case studies at the London Vet Show 2019, Dr Ciaran Jones explains how he uses Galliprant for conservative management of OA.

Galliprant in Practice Webinar/Video (43 mins)

Drawing on his years of experience, Dr Ciaran Jones MVB MS MRCVS DECVS DACVS shares case studies and experience of Galliprant in practice. He also explores how owners feel abo...

Name of the veterinary medicinal product: Galliprant 20 mg, 60 mg, and 100 mg tablets for dogs.

^*Indication: Galliprant is indicated for the treatment of pain associated with mild to moderate osteoarthritis in dogs. Side effects, precautions, warnings and contraindications: Refer to the product packaging and leaflets for information about side effects, precautions, warnings and contraindications. Storage: Do not store above 30°C. Any half tablets should be stored in the bottle. In order to avoid any accidental ingestion, store tablets out of reach of animals.

^†As field studies were limited to 28 days, longer-term treatment should be considered carefully and regular monitoring undertaken by the vet.

Galliprant contains grapiprant. Legal category POM-V (UK) POM (IE).

Further information is available from the Summary of Product Characteristics or datasheet. Advice should always be sought from the medicine prescriber. Information on this veterinary medicinal product is available on the website of the European Medicines Agency https://www.ema.europa.eu. For further information call Elanco Animal Health on +44(0)1256 353131 or write to: Elanco UK AH limited, Form 2, Bartley Way, Bartley Wood Business Park, Hook, RG27 9XA.

Use medicines responsibly www.noah.co.uk/responsible (UK); www.apha.ie (IE).